According to the release, data from the 28-week, randomized-controlled N-MOmentum trial showed that 89% of 161 patients in the Uplizna (inebilizumab-cdon, Horizon News News CME CME ...

--Amgen announced today that the U.S. Food and Drug Administration has approved UPLIZNA as the first and only treatment for adults living with Immunoglobulin G4-related disease. "The FDA approval ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth out of another drug from its $27.8 billion Horizon Therapeutics buy.

Horizon Therapeutics plc today announced new data from two post-hoc analyses of the N-MOmentum clinical trial of UPLIZNA for the treatment of neuromyelitis optica spectrum disorder will be ...

Uplizna reduced the risk of IgG4-RD flare by 87%, with 10.3% of patients on Uplizna experiencing a flare versus 59.7% on placebo. 58.8% of Uplizna patients achieved flare-free, corticosteroid-free ...

Uplizna (inebilizumab-cdon) is now the first and only FDA-approved treatment for IgG4-related disease. News release. Amgen; April 3, 2025. Accessed April 3, 2025.

Horizon Therapeutics announced positive results of MRI data from the phase 3 clinical trial of Uplizna, which showed reduction in formation of subclinical transverse myelitis lesions in patients ...

Uplizna was one of the key drugs acquired from the company’s $27.8 billion acquisition of Horizon Therapeutics, which was completed in October of last year. Amgen Uplizna Myasthenia Gravis ...

72.3% of AChR+ patients on Uplizna saw a ≥3-point MG-ADL score improvement vs. 45.2% on placebo. Uplizna is under FDA priority review for IgG4-related disease with a PDUFA date of April 3 ...

JHVEPhoto. Amgen (NASDAQ:AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs rocatinlimab and Uplizna.Late Tuesday, Amgen released data from a ...

UPLIZNA ® (inebilizumab-cdon) is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.